Program
The program of the International RAB symposium on regulatory autoantibodies targeting G-protein-coupled receptors will address the field of GPCR antibody research with specific highlights on:
- anti-GPCR antibodies as biomarker in disease and therapeutic response
- anti-GPCR antibody-mediated pathways
- regulation of anti-GPCR abs
- Identification of novel therapeutic targets
Why to join?
Our aim is to bring scientists together, initiate discussions and stimulate research on these challenges. We would like to strengthen the research network to:
- identify new pathogenic targets, biomarkers and signalling pathways to find a holistic way to understand diseases
- To identify effectors that influence the disease-specific transcriptome and secretome
- understand how environmental factors and genes can be transformed into molecular pathways
- Develop novel therapeutic strategies
Thursday, 15.09.2022
| Time | Title |
| Provocative statements | |
| 09:00 | All diseases are autoimmune diseases Y. Shoenfeld |
| 09:30 | All diseases are GPCR abs mediated diseases G. Riemekasten |
| 10:00 | Coffee break |
| COVID-19 and natural regulatory abs | |
| 10:30 | Anti-GPCR and acute COVID infection F.Tran |
| 11:00 | COVID-Vaccination and anti-GPCR abs T. Lange |
| 11:30 | Role of GPCR abs in Post-COVID syndrome C. Scheibenbogen |
| 12:00 | Lunch break |
| 13:45 | Poster Session |
| Progress in preclinical models to measure RAB ab effects | |
| 14:30 | Animal models X. Yu |
| 15:00 | Modification of animal models and GPCR/monoclonal abs F. Petersen |
| 15:30 | Stroke and anti-GPCR abs M. Endres |
| 16:00 | Coffee break |
| Anti-GPCR binding biology | |
| 16:30 | Glycocalix and their interplay with GPCR abs K. Kusche-Viehrog |
| 17:00 | Ab binding by measuring the crystal structures of GPCRs P. Scherer |
| 17:30 | Biology of regulatory abs, insight from bioinformatics O. Cabral Marques |
| 18:30 | Get together, Networking in the industrial exhibition |
Friday, 15.09.2022
| Time | Title |
| Natural RAB-induced signalling | |
| 09:00 | What comes after ab binding? How to go beyond the cell surface? E. Kostenis |
| 09:30 | Signalling of GPCR abs in different cellular models R. Catar |
| 10:00 | Ab-induced proteome H. Grasshoff |
| 10:30 | Coffee break |
| Therapy | |
| 11:30 | Aptamer BQ007, a novel therapeutic agent? B. Hohenberger |
| 12:00 | Interacting with GPCR by peptides J. Bernhagen |
| 12:30 | Lunch and Postersession |
| Fibromyalgia and ME/CSF as another challenge | |
| 14:00 | Fibromyalgia: ab-mediated pathogenesis C. I. Svensson |
| 14:30 | GPCR abs and confounding factors: Learning from fibromyalgia F. Lübbers |
| 15:00 | Role of GPCR abs in chronic fatigue syndrome F. Sotzny |
| 15:30 | Coffee break |
| New pathogenesis insights from SSc | |
| 16:00 | GPCR abs in systemic sclerosis S. Schinke |
| 16:30 | Measuring GPCR ab characteristics A. Kehrstein-Stehle |
| 17:00 | GPCR abs and EVs as the bad boys affecting immune cell functions A. Hackel |
| Lecture | |
| 17:30 | EVs and antibody-interactions D. Pisetzky |
| What are the next steps, how to proceed? | |
| 18:15 | General discussion |